Survodutide Research & Studies
We track 20 published, PubMed-indexed studies for Survodutide, spanning 2023 to 2026. The research below includes 11 clinical trials, 4 meta-analysiss, 5 reviews.
These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
11
Clinical Trials
4
Meta-Analysiss
5
Reviews
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).
Clinical Trialle Roux CW, Wharton S, et al.|Diabetes Obes Metab|2026
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.
Clinical TrialWharton S, le Roux CW, et al.|Diabetes Obes Metab|2026
Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.
Meta-AnalysisXiao YJ, Yu S, et al.|Diabetes Obes Metab|2025
Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.
Meta-AnalysisSouza M, Al-Sharif L, et al.|Hepatology|2025
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.
Meta-AnalysisWang Y, Zhou Y, et al.|J Clin Endocrinol Metab|2025
Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.
Meta-AnalysisSinha B, Ghosal S|Obesity (Silver Spring)|2025
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).
Clinical TrialWharton S, le Roux CW, et al.|Obesity (Silver Spring)|2025
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m(2) in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.
Clinical Trialle Roux CW, Steen O, et al.|Diabetes Obes Metab|2025
Emerging pharmacotherapies for obesity: A systematic review.
ReviewKokkorakis M, Chakhtoura M, et al.|Pharmacol Rev|2025
Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.
ReviewNewsome PN, Loomba R|J Clin Invest|2025
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
Clinical TrialSanyal AJ, Bedossa P, et al.|N Engl J Med|2024
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
Clinical Trialle Roux CW, Steen O, et al.|Lancet Diabetes Endocrinol|2024
Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Clinical TrialBlüher M, Rosenstock J, et al.|Diabetologia|2024
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
Clinical TrialLawitz EJ, Fraessdorf M, et al.|J Hepatol|2024
Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.
Clinical TrialKosiborod MN, Platz E, et al.|JACC Heart Fail|2024
Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction.
ReviewKaya E, Yilmaz Y, Alkhouri N|Expert Opin Investig Drugs|2024
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
ReviewDrucker DJ|Diabetes Care|2024
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.
ReviewStefanakis K, Kokkorakis M, Mantzoros CS|Metabolism|2024
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.
Clinical TrialJungnik A, Arrubla Martinez J, et al.|Diabetes Obes Metab|2023
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.
Clinical TrialYazawa R, Ishida M, et al.|Diabetes Obes Metab|2023